"Baseline Blood Cell Sample for 8mg Dosage Group from Female Patient Aged 55"
This study involves the sequencing of targeted DNA fragments from serum and blood cell samples collected from cancer patients undergoing treatment at different dosage levels. The objective is to identify genetic variations that influence treatment efficacy and patient outcomes. Samples were collected at baseline, after 37 days of treatment, during treatment, and at the end of the treatment period. Sequencing was performed on the Illumina HiSeq X Ten platform using a targeted hybrid capture approach for dual-end reads to ensure comprehensive coverage of all targeted gene regions. The study aims to correlate these genetic markers with clinical responses in different dosage groups.